LX102 C01
Alternative Names: LX 102 C 01; LX-102Latest Information Update: 12 Jan 2024
At a glance
- Originator Innostellar Biotherapeutics
- Developer Innostellar Biotherapeutics; Shanghai General Hospital
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Wet age-related macular degeneration
- Clinical Phase Unknown Age-related macular degeneration
Most Recent Events
- 21 Dec 2023 Phase-II clinical trials in Wet-age-related macular degeneration (Treatment-experienced) in China (Subretinal) (NCT06196840)
- 06 Dec 2021 Clinical trials in Age-related macular degeneration (Treatment-experienced, In adults, In the elderly) in China (Intravitreous) (NCT05831007)